ReviewJournal of neurology2025
The diagnostic value of plasma Aβ42 and Aβ40 in Alzheimer's disease: current status, challenges, and impacting variables.
Review in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a group of central nervous system degenerative diseases that affect cognitive function. During the diagnosis of AD, the levels of amyloid-β 42 (Aβ42) and amyloid-β 40 (Aβ40) in plasma, as well as their ratio Aβ42/Aβ40, have recently been recommended by the International Association for the Study of Aging and Alzheimer's Disease as biomarkers to assist in clinical decision-making. However, an increasing amount of research data indicates that the effectiveness of these biomarkers is influenced by various factors. The levels of Aβ42 and Aβ40 are not only related to the physiological state of the human body, but also closely associated with the collection and preservation of plasma samples, pre-analytical processing, different detection methodologies, and even the result analysis process. Moreover, the functional status of metabolic organs in the human body, different comorbidities, bacterial or viral infections, and other factors can all affect the true levels of Aβ42 and Aβ40. Therefore, to clearly and comprehensively understand the advantages and limitations of plasma Aβ42 and Aβ40 as diagnostic biomarkers for AD, this article focuses on reviewing and discussing the influencing factors when plasma Aβ42 and Aβ40 are applied to the diagnosis of AD, aiming to help clinicians make better use of these indicators to optimize their diagnostic value.
Indexed as
Identifiers
41405709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.